he renin-angiotensin system (RAS) plays an important role in the regulation of the cardiovascular system in various physiological or pathological conditions 1 and is activated on acute myocardial infarction both in humans 2 and in experimental animals. 3,4 Angiotensin II (Ang II) increases myocardial necrosis. 5 The localized Ang II exerts some deleterious effects on the myocardium of ischemia-reperfused heart. 6 Angiotensin II type 1 (AT1) receptor antagonists have the cardioprotective effect on ischemia-reperfusion injury. 7,8 And also, AT1 receptor antagonists have been shown to involve AT2 receptor activation and the subsequent action of bradykinin. 9 Recent evidence suggests that the adenosine triphosphate-sensitive K + (KATP) channels are mainly involved in effectors of cardioprotection against ischemia-reperfusion. 10,11 A reducJapanese Circulation Journal Vol.65, May 2001 tion in myocardial damage, reduced formation of Ang II, preservation of bradykinin, or opening of KATP channels could all play the role. The effect of AT1 receptor antagonists against the KATP channels in myocardial ischemiareperfusion injury is not clearly identified.The purpose of the present study was to test the hypothesis that AT1 receptor antagonist contributes to the cardioprotective effect in the ischemia-reperfused heart by acting against KATP channels through the bradykinin B2 receptor or not. We measured the effects of AT1 receptor antagonist on myocardial energy metabolism by using phosphorus 31-nuclear magnetic resonance ( 31 P-NMR spectrometer) and assessed cardiac function in isolated rabbit heart. The administration of this agent was found to improve abnormal myocardial energy metabolism and relaxation by acting against KATP channels through the bradykinin B2 receptor.
Methods
Isolated Heart PreparationMale, Japanese white rabbits weighing 1.6-1.7 kg were anesthetized by intravenous injection of sodium pentobar- . Group II showed a significant inhibition of the decrease in ATP during ischemia and reperfusion compared with Group I (p<0.01), being 42±3% and 19±4% at ischemia, 69±3% and 47±4% at reperfusion in Group II and Group I, respectively. Group II also showed a significant inhibition of the increase in LVEDP during ischemia and reperfusion compared with Group I (p<0.01), being 13±4 mmHg and 52±8 mmHg at ischemia, 8±2 mmHg and 26±5 mmHg at reperfusion in Group II and Group I, respectively. However, Group III did not inhibit the decrease in ATP and the increase in LVEDP during ischemia and reperfusion. Group IV also showed no inhibition of the aforementioned parameters during the same period. These results suggest that CV-11974 has a significant beneficial effect for improving myocardial energy metabolism and relaxation during both myocardial ischemia and reperfusion, which is provided by KATP channels and bradykinin B2 receptor. The cardioprotective quality of the AT1 receptor antagonist is caused by the KATP channels that are mediated by the bradykinin B2 receptor. (Jpn Circ J 2001; 65: 451 -456)